ShockWave Medical, Inc. (NASDAQ:SWAV) VP Trinh Phung Sells 3,176 Shares

ShockWave Medical, Inc. (NASDAQ:SWAVGet Rating) VP Trinh Phung sold 3,176 shares of the company’s stock in a transaction that occurred on Tuesday, April 12th. The stock was sold at an average price of $215.61, for a total transaction of $684,777.36. Following the completion of the transaction, the vice president now owns 29,695 shares in the company, valued at $6,402,538.95. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ShockWave Medical stock opened at $209.71 on Friday. The company has a fifty day simple moving average of $176.98 and a 200-day simple moving average of $183.89. ShockWave Medical, Inc. has a 12-month low of $125.00 and a 12-month high of $249.73. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.05.

ShockWave Medical (NASDAQ:SWAVGet Rating) last announced its quarterly earnings results on Thursday, February 17th. The company reported $0.34 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.27. ShockWave Medical had a negative net margin of 3.85% and a negative return on equity of 4.18%. The firm had revenue of $84.18 million for the quarter, compared to analyst estimates of $75.27 million. During the same period last year, the business earned ($0.46) EPS. On average, equities research analysts expect that ShockWave Medical, Inc. will post 1.47 earnings per share for the current fiscal year.

Several equities analysts have recently commented on the stock. Morgan Stanley decreased their price objective on shares of ShockWave Medical from $210.00 to $199.00 and set an “equal weight” rating on the stock in a report on Friday, February 18th. Piper Sandler reduced their target price on shares of ShockWave Medical from $272.00 to $245.00 in a report on Friday, February 18th. Bank of America assumed coverage on shares of ShockWave Medical in a report on Wednesday, March 2nd. They set a “buy” rating on the stock. SVB Leerink increased their target price on shares of ShockWave Medical from $160.00 to $190.00 and gave the stock an “outperform” rating in a report on Friday, February 18th. Finally, Wolfe Research assumed coverage on shares of ShockWave Medical in a report on Tuesday, April 5th. They set an “outperform” rating and a $255.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $220.33.

Large investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. raised its stake in ShockWave Medical by 104.9% during the 4th quarter. Rockefeller Capital Management L.P. now owns 166 shares of the company’s stock worth $29,000 after acquiring an additional 85 shares in the last quarter. C M Bidwell & Associates Ltd. acquired a new position in ShockWave Medical in the third quarter valued at $38,000. PNC Financial Services Group Inc. increased its stake in ShockWave Medical by 30.3% in the third quarter. PNC Financial Services Group Inc. now owns 202 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the period. First Horizon Advisors Inc. increased its stake in ShockWave Medical by 67.7% in the fourth quarter. First Horizon Advisors Inc. now owns 260 shares of the company’s stock valued at $45,000 after purchasing an additional 105 shares during the period. Finally, Financial Management Professionals Inc. increased its stake in ShockWave Medical by 1,020.8% in the third quarter. Financial Management Professionals Inc. now owns 269 shares of the company’s stock valued at $55,000 after purchasing an additional 245 shares during the period. Hedge funds and other institutional investors own 93.15% of the company’s stock.

About ShockWave Medical (Get Rating)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Recommended Stories

Insider Buying and Selling by Quarter for ShockWave Medical (NASDAQ:SWAV)

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.